AI assistant
C4 Therapeutics, Inc. — Director's Dealing 2021
Aug 6, 2021
33861_dirs_2021-08-05_9abca5fd-88ba-4c9f-b9bf-734bae1d3336.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-08-03
Reporting Person: Prokupets Elena (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-03 | Common Stock | S | 14407 | $45.1577 | Disposed | 88574 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 592873 | Indirect |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.